| scholarly article | Q13442814 |
| P2093 | author name string | Yu-Shu Huang | |
| Chih-Ken Chen | |||
| Shao-Chun Ree | |||
| Cheng-Cheng Hsiao | |||
| P2860 | cites work | The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10 | Q29547745 |
| Switching patients to aripiprazole from other antipsychotic agents: a multicenter randomized study | Q33186211 | ||
| The Barnes Akathisia Rating Scale--revisited | Q33975805 | ||
| Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management | Q34551484 | ||
| Prolactin elevation with antipsychotic medications: mechanisms of action and clinical consequences | Q34576892 | ||
| Antipsychotic-induced hyperprolactinaemia in women: pathophysiology, severity and consequences. Selective literature review | Q35075413 | ||
| Evidence for the partial dopamine-receptor agonist aripiprazole as a first-line treatment of psychosis in patients with iatrogenic or tumorogenic hyperprolactinemia | Q37581247 | ||
| A multicenter, randomized, double-blind, placebo-controlled, 16-week study of adjunctive aripiprazole for schizophrenia or schizoaffective disorder inadequately treated with quetiapine or risperidone monotherapy | Q38377724 | ||
| Elevation of prolactin levels by atypical antipsychotics | Q43843058 | ||
| Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors | Q44028935 | ||
| The differential effects of atypical antipsychotics on prolactin elevation are explained by their differential blood-brain disposition: a pharmacological analysis in rats | Q44106412 | ||
| Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials | Q44428863 | ||
| A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania | Q44565868 | ||
| Effects of aripiprazole on prolactin levels in subjects with schizophrenia during cross-titration with risperidone or olanzapine: analysis of a randomized, open-label study | Q46225391 | ||
| Time course of the changes in antipsychotic-induced hyperprolactinemia following the switch to aripiprazole | Q46320767 | ||
| Reversal of symptomatic hyperprolactinemia by aripiprazole | Q46628167 | ||
| Reversal of antipsychotic-induced hyperprolactinemia, weight gain, and dyslipidemia by aripiprazole: A case report. | Q47322099 | ||
| Using aripiprazole to resolve antipsychotic-induced symptomatic hyperprolactinemia: a pilot study | Q50113851 | ||
| Neuroendocrine response to antipsychotics: effects of drug type and gender. | Q50539422 | ||
| Adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. | Q51740194 | ||
| A rating scale for extrapyramidal side effects | Q53780342 | ||
| Acute antagonism of dopamine D2-like receptors by amisulpride: effects on hormone secretion in healthy volunteers | Q72647414 | ||
| The Arizona Sexual Experience Scale (ASEX): reliability and validity | Q73488950 | ||
| Amisulpride-induced hyperprolactinaemia is not reversed by addition of aripiprazole | Q80190861 | ||
| P433 | issue | 8 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | risperidone | Q412443 |
| P304 | page(s) | 1495-1499 | |
| P577 | publication date | 2010-08-20 | |
| P1433 | published in | Progress in Neuro-Psychopharmacology & Biological Psychiatry | Q15616665 |
| P1476 | title | Differential add-on effects of aripiprazole in resolving hyperprolactinemia induced by risperidone in comparison to benzamide antipsychotics | |
| P478 | volume | 34 |
| Q89136911 | Adjunct Aripiprazole Reduces Prolactin and Prolactin-Related Adverse Effects in Premenopausal Women With Psychosis: Results From the DAAMSEL Clinical Trial |
| Q30490025 | Adjunctive aripiprazole in risperidone-induced hyperprolactinaemia: double-blind, randomised, placebo-controlled trial. |
| Q37895702 | Antipsychotic-induced hyperprolactinaemia |
| Q47645310 | Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research |
| Q38020263 | Critical review of antipsychotic polypharmacy in the treatment of schizophrenia |
| Q37155297 | Effect of aripiprazole on cognitive function and hyperprolactinemia in patients with schizophrenia treated with risperidone |
| Q37300013 | Euprolactinemic gynecomastia and galactorrhea with risperidone-fluvoxamine combination. |
| Q94561344 | Immunoendocrine Peripheral Effects Induced by Atypical Antipsychotics |
| Q89329466 | Management of antipsychotic-induced hyperprolactinemia |
| Q39149871 | Multidisciplinary consensus on the therapeutic recommendations for iatrogenic hyperprolactinemia secondary to antipsychotics. |
| Q36972523 | Paliperidone and aripiprazole differentially affect the strength of calcium-secretion coupling in female pituitary lactotrophs |
| Q38538492 | Relationship between prolactin, breast cancer risk, and antipsychotics in patients with schizophrenia: a critical review |
| Q38769838 | Safety and tolerability of antipsychotic co-treatment in patients with schizophrenia: results from a systematic review and meta-analysis of randomized controlled trials |
| Q36062421 | Safety and tolerability of antipsychotic polypharmacy |
| Q64330025 | TARC: Turkish aripiprazole consensus report- Aripiprazole use and switching from other antipsychotics to aripiprazole- consensus recommendations by a Turkish multidisciplinary panel |
| Q33619940 | The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. |
| Q37533845 | Treating symptomatic hyperprolactinemia secondary to a long-acting injectable atypical antipsychotic in a patient with bipolar disorder due to an anoxic brain injury |
Search more.